What is it about?
This paper describes an economic evaluation of lenalidomide for transfusion-dependent patients with Low/Intermediate-1-risk MDS del 5q from the perspective of the public health care sector in Mexico.
Featured Image
Why is it important?
The econonomic evaluation is a important tool to take decisions in health, in this particular case to benefit patients with with Low/Intermediate-1-risk MDS del 5q.
Perspectives
In Mexico, innovative therapies face different challenges to be covered by the public health system. One of the key points is to use the resources looking for the maximum clinical benefit, for that reason, we are looking to make decisions based on evidence. In this sense, the economic evaluation of medicines allows the efficient use of resources and facilitates the access of patients such as those with Myelodysplastic Syndromes, to innovative therapies with proven clinical benefits.
Arely Lemus Carmona
Celgene Corp
Read the Original
This page is a summary of: Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1, Global & Regional Health Technology Assessment, January 2017, SAGE Publications,
DOI: 10.5301/grhta.5000256.
You can read the full text:
Contributors
The following have contributed to this page
